Today Motivant completes its acquisition of Beverly Hills Rejuvenation Center. After twenty years as one of the most recognized longevity and regenerative-aesthetics brands in the country, BHRC joins the firm as the consumer-facing layer of the integrated life-sciences stack our principals have been building for the better part of a decade. I am honored to step in as Chief Executive Officer.
This is the most important transaction in our firm's history, and the one that makes our public thesis physically real. Until today, the words "verticalized, client-centric ecosystem through biotech integration" described what we were building. Today they describe what we operate.
A twenty-year operating company, not a turnaround
BHRC was founded in 2005. Over twenty years it has grown to roughly twenty-four locations across California, Nevada, Texas, and Arizona, a roster of corporate-owned and franchised centers, and a clinical service line that spans longevity medicine, regenerative aesthetics, hormone and peptide therapy, GLP-1-based weight programs, and the Cell Factor regenerative protocols.
We are not buying a fixer-upper. We are buying a credible operator with a proven service category, an installed base of relationships with proprietary technology partners — Solaria by InMode, EmSculpt Neo and EmFace and Exion from BTL Aesthetics, Cell Factor — and a brand that already commands roughly a five-hundred-dollar average ticket in the consumer wellness market.
What we are bringing is what a family office can bring that a fund cannot: an indefinite holding period, the diagnostic infrastructure of our laboratory portfolio, and the operating posture to relaunch the franchise model that previous ownership had paused.
Why this acquisition, why now
The thesis behind BHRC is the thesis behind the rest of our life-sciences work, applied at the consumer end of the chain.
The diagnostics layer of the firm — Marquis Labs in Oklahoma City, Cellestiq, Rio Grande Valley Labs in Alamo, Texas — generates proprietary molecular data on patient health every day. The education layer — Asciere, RegenTherapy — frames which protocols are credible for clinical use. BHRC is where those protocols get delivered to a real patient sitting in a real chair on a Tuesday morning.
Building those three layers separately and hoping they would later interlock would have been the slow path. Owning the consumer-facing endpoint outright is the fast path. Today is the day the chain closes.
Owning the consumer-facing endpoint of our life-sciences stack outright is the fast path. Today is the day the chain closes.
The bench coming with us
The team taking BHRC into its next chapter has been built deliberately. Dr. Arvind Chakravarthy joins as Chief Longevity Officer — the clinical leader most associated with the regenerative-medicine education work at RegenTherapy and the public voice on care-pillar regimen design. Sanjiv Lal, our co-founder and partner, brings the laboratory infrastructure and the regenerative IP relationships into the operating equation. Sam Brooks, our other co-founder and partner, brings the operating playbook from his time scaling laboratory services past one-hundred-fifty million dollars and national telecommunications operations past two-hundred-seventy-five million. Sal Afridi, our Chief Financial Officer, leads the integration on the operating-finance side.
What this means in practice is that every consequential decision at BHRC sits inside the operator's room, not on a list passed up to a board.
What's next
Three things in the immediate term.
First, the West Hollywood Center of Excellence opens later this year as our new flagship clinic and the visible signal of what BHRC under Motivant looks like. More on that as we get closer to opening day.
Second, we are reopening the franchise model. Previous ownership paused franchising; we are not just resuming it but actively courting multi-unit operators in every major U.S. market. The franchise opportunity inside BHRC is one of the strongest in the consumer-wellness category we have seen in years, and we intend to grow into it.
Third, every BHRC location moves, on day one, into the integrated diagnostics-and-protocols stack the rest of the firm operates. That is the single biggest operating change a center will see post-acquisition: the science behind what gets delivered in the chair becomes our science.
For everyone — patients, franchisees, employees, clinical partners, and the public who has watched this category grow up over the past twenty years — what changes today is the firm behind the brand. What does not change is the brand itself, the standards in the chair, or the clinical promise patients walk in expecting.
I'm grateful to be the one taking this on. More to follow.
